Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
(2511.HK), a biopharmaceutical company specialising in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM)
Retrieved from Sun, X
That was all
Reduced appetite can make protein planning more important
US$ 28.22
US$ 29.76
US$ 29.48
US$ 21.26
US$ 28.42
US$ 25.98
US$ 20.86
US$ 21.53
US$ 24.36
US$ 23.56
US$ 25.04
US$ 29.66
